Publications

2019

Susan WyllieStephen BrandMichael ThomasManu De Rycker et al. (2019) Preclinical candidate for the treatment visceral leishmaniasis acts through proteasome inhibition. PNAS. https://www.ncbi.nlm.nih.gov/pubmed/30962368

Corpas-Lopez, V., Moniz, S., Thomas, M., Wall, R. J., Torrie, L. S., Zander-Dinse, D. Tinti, M., Brand, S., Stojanovski, L., Manthri, S., Hallyburton, I., Zuccotto, F., Wyatt, P. G., De Rycker, M., Horn, D., Ferguson, M. A. J., Clos, J., Read, K. D., Fairlamb, A.H., Gilbert, I. H. and Wyllie, S. (2019) Pharmacological validation of N-myristoyltransferase as a drug target in Leishmania donovani. ACS Infect Dis. 5: 111–122. https://www.ncbi.nlm.nih.gov/pubmed/30380837

2018

Fersing, C., Basmaciyan, L., Boudot, C., Pedron, J., Hutter, S., Cohen, A., Castera-Ducros, C., Primas, N., Laget, M., Casanova, M., Bourgeade-Delmas, S., Piednoel, M., Sournia-Saquet, A., Belle Mbou, V., Courtioux, B., Boutet-Robinet, E., Since, M., Milne, R., Wyllie, S., Fairlamb, A. H., Valentin, A., Rathelot, P., Verhaeghe, P., Vanelle, P., Azas, N. (2018) Non-genotoxic 3-nitroimidazo[1,2-a]pyridines are NTR1 substrates that display potent in vitro antileishmanial activity. ACS Med Chem Lett. 10: 34-39. https://www.ncbi.nlm.nih.gov/pubmed/30655943

Webster, L. A., Thomas, M., Urbaniak, M., Wyllie, S., Ong, H. B., Tinti, M., Fairlamb, A. H., Boesche, M., Ghidelli-Disse, S., Drewes, G. and Gilbert, I. H. (2018) Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome. ACS Infect Dis. 4: 1475-1486. https://www.ncbi.nlm.nih.gov/pubmed/30264983

Pedron, J., Boudot, C., Bourgeade-Delmas, S. et al. (2018) Antitrypanosomatid Pharmacomodulation at Position 3 of the 8-Nitroquinolin-2(1H)-one Scaffold Using Palladium-Catalysed Cross-Coupling Reactions. ChemMedChem. 13: 2217-2228. https://www.ncbi.nlm.nih.gov/pubmed/30221468

Wall, R.J., Rico, E., Lukac, I., Zuccotto, F., Elg, S., Gilbert, I. H., Freund, Y., Alley, M. R. K., Field, M. C., Wyllie, S. and Horn D. (2018) Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. PNAS 115: 9616-9621. https://www.ncbi.nlm.nih.gov/pubmed/30185555

Fersing, C., Boudot, C., Pedron, J. et al. (2018) 8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases. Eur J Med Chem. 157:115-126. https://www.ncbi.nlm.nih.gov/pubmed/30092366

Wyllie, S. Thomas, M., Patterson, S. et al. (2018) Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis. Nature 560:192-197. https://www.ncbi.nlm.nih.gov/pubmed/30046105

Pedron, J., Boudot, C., Hutter, S. et al. (2018) Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study. Eur J Med Chem. 155:135-152. https://www.ncbi.nlm.nih.gov/pubmed/29885575

Wall, R. J., Moniz, S., Thomas, M. G., Norval, S., Ko, E. J., Marco, M., Miles, T. J., Gilbert, I. H., Horn, D., Fairlamb, A. H. and Wyllie S. (2018) Anti-trypanosomal 8-hydroxy naphthyridines are chelators of divalent transition metals. Antimicrob Agents Chemother. 62. pii: e00235-18. https://www.ncbi.nlm.nih.gov/pubmed/29844044

2017

Torrie, L. S, Brand, S. Robinson, D. A. et al. (2017) Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infect Dis. 3: 718-727. https://www.ncbi.nlm.nih.gov/pubmed/28967262

Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S. and Gilbert, I. H. (2016) Antitrypanosomatid drug discovery: An ongoing challenge and a continuing need. Nature Rev. Microbiol. 15, 217-231. https://www.ncbi.nlm.nih.gov/pubmed/28579611

2016

Wyllie, S., Norval, S., Roberts, A. J., Patterson, S., Foth, B. J., Berriman, M., Read, K. D. and Fairlamb, A. H.   (2016) Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania. PLoS Pathog. e1005971. https://www.ncbi.nlm.nih.gov/pubmed/27812217